ORPHA:213711
Endometrial stromal sarcoma
Also known as: Stromal sarcoma of the corpus uteri
Publications
3,585
Trials
9
Interventional, condition-specific
Researchers
1,233
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0006745
- MeSH:D018203
- UMLS:C0206630
- NCIT:C8973
Additional Mondo synonyms (10)
ESS · endometrial stromal sarcoma · endometrial stromal sarcomas · endometrioid stromal sarcoma · ess · sarcomas, endometrial stromal · stromal sarcoma of the corpus uteri · stromal sarcoma, endometrial · stromal sarcoma, endometrial, malignant · stromal sarcomas, endometrial
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
3,585 matched papers (2,044 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
9 matched on ClinicalTrials.gov (3 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
3
Drugs / clinical candidates · MONDO_0006745
- CABOZANTINIB·phase 2
- MIFEPRISTONE·phase 2
- SELINEXOR·phase 1
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
3,585
3,585 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
3,585 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
2,044 in the last 10 years · low confidence
Phrase hits: 3,584 · MeSH hits: 4
Who's working on it?
1,233
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Liu Y7 papers · 2026
Department of Gynaecology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, Shandong Province, PR China.
Papers in Europe PMC - 02Croce S6 papers · 2026
Department of BioPathology, Anticancer Center, Institut Bergonié, Bordeaux, France; Unité INSERM U1218, Bordeaux, France; Gynecological Pathology Group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France. Electronic address: s.croce@bordeaux.unicancer.fr.
Papers in Europe PMC - 03Chiang S5 papers · 2026
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
Papers in Europe PMC - 04Oliva E5 papers · 2025
James Homer Wright Pathology Laboratories, Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Papers in Europe PMC - 05Wang J5 papers · 2026
Department of Ultrasound, West China Second University Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Chengdu, China. quyangjinwangfu@163.com.
Papers in Europe PMC - 06Zhang L5 papers · 2026
University of Toronto, Department of Laboratory Medicine and Pathobiology, Toronto, ON, Canada.
Papers in Europe PMC - 07Ciccarone F4 papers · 2026
Gynecologic Oncology Unit, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario 'A. Gemelli' IRCCS, Rome, Italy.
Papers in Europe PMC - 08Dundr P4 papers · 2026
Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Papers in Europe PMC - 09Lee CH4 papers · 2026
Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB.
Papers in Europe PMC - 10Li L4 papers · 2026
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Shuaifuyuan No. 1, Dongcheng District, Beijing, 100730, China. lileigh@163.com.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
9
interventional trials for this specific condition
9 interventional trials matched this specific condition name; 3 currently recruiting in our sample. 1,647 trials are registered for sarcoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
9 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 92th percentile).
low confidence · 92th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
9 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT03624244·RECRUITING·Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)
Not reviewed·Conditions: Low Grade Endometrial Stromal Sarcoma·Matched via name phrase
- NCT06277154·RECRUITING·MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
Not reviewed·Conditions: Leiomyosarcoma · Liposarcoma · Synovial Sarcoma · Angiosarcoma·Matched via name phrase
- NCT07467772·RECRUITING·Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Not reviewed·Conditions: Uterine Sarcoma · Uterine Leiomyosarcoma · Endometrial Stromal Sarcoma · ESS·Matched via name phrase
Broader category: sarcoma
1,647
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07359053·RECRUITING·MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma
Not reviewed·Conditions: Sarcoma·Matched via name phrase
- NCT06805773·RECRUITING·Evaluating the Use of Educational Videos in Newly Diagnosed Patients in a Medical Oncology Sarcoma Clinic
Not reviewed·Conditions: Sarcoma·Matched via name phrase
- NCT07460986·NOT YET RECRUITING·A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA
Not reviewed·Conditions: Sarcoma of Soft Tissue·Matched via name phrase
- NCT07134192·RECRUITING·Fluorescence-Guided Optimization of Sarcoma Margins
Not reviewed·Conditions: Soft Tissue Sarcoma of the Trunk and Extremities · Sarcoma·Matched via name phrase
- NCT01659203·RECRUITING·Proton or Photon RT for Retroperitoneal Sarcomas
Not reviewed·Conditions: Retroperitoneal Sarcoma·Matched via name phrase
- NCT07032285·RECRUITING·Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas
Not reviewed·Conditions: Soft Tissue Sarcoma (STS)·Matched via name phrase
- NCT07308886·RECRUITING·Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
Not reviewed·Conditions: Kaposi Sarcoma·Matched via name phrase
- NCT06789666·RECRUITING·Digital Art Therapy for Young Cancer Survivors
Not reviewed·Conditions: Cancer · Pediatric Cancer · Pediatric Malignancies · Pediatric Sarcoma of Soft Tissue·Matched via name phrase
- NCT07052383·RECRUITING·Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas
Not reviewed·Conditions: Osteosarcoma · Soft Tissue Sarcoma·Matched via name phrase
- NCT06066138·RECRUITING·A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Not reviewed·Conditions: Locally Advanced Alveolar Soft Part Sarcoma · Metastatic Alveolar Soft Part Sarcoma · Locally Advanced Non Small Cell Lung Cancer · Metastatic Non Small Cell Lung Cancer·Matched via name phrase
- NCT06498648·RECRUITING·Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
Not reviewed·Conditions: Advanced Dedifferentiated Liposarcoma · Advanced Leiomyosarcoma · Advanced Soft Tissue Sarcoma · Metastatic Dedifferentiated Liposarcoma·Matched via name phrase
- NCT05918640·RECRUITING·Lurbinectedin in FET-Fused Tumors
Not reviewed·Conditions: Ewing Sarcoma · Desmoplastic Small Round Cell Tumor · Pediatric Cancer · Undifferentiated Sarcoma·Matched via name phrase
- NCT06371768·RECRUITING·Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
Not reviewed·Conditions: Cancer · Breast Cancer · Colorectal Cancer · Sarcoma·Matched via name phrase
- NCT04698785·RECRUITING·Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients
Not reviewed·Conditions: Bone Sarcoma · Osteosarcoma·Matched via name phrase
- NCT05182164·RECRUITING·Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
Not reviewed·Conditions: Soft Tissue Sarcoma Adult · Advanced Soft-tissue Sarcoma · Ewing Sarcoma · Osteosarcoma·Matched via name phrase
Observational and natural-history studies
2 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 1 · after dedupe 1 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 1 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (1)
- ctis·2024-512629-97-00·Authorised, ongoing·BFR ESS - A randomized comparative, prospective, multicentre phase II study evaluating the clinical impact of interruption versus maintenance of aromatase inhibitors in patients with locally advanced or metastatic low grade endometrial stromal sarcoma
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Endometrial stromal sarcoma — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Endometrial stromal sarcoma" OR "Stromal sarcoma of the corpus uteri" OR "Stromal sarcoma of corpus uteri" OR "endometrial stromal sarcomas" OR "endometrioid stromal sarcoma" OR "sarcomas, endometrial stromal" OR "stromal sarcoma, endometrial" OR "stromal sarcoma, endometrial, malignant" OR "stromal sarcomas, endometrial"
MeSH descriptor terms unioned into the query: Sarcoma, Endometrial Stromal
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Endometrial stromal sarcoma" OR "Stromal sarcoma of the corpus uteri" OR "Stromal sarcoma of corpus uteri" OR "endometrial stromal sarcomas" OR "endometrioid stromal sarcoma" OR "sarcomas, endometrial stromal" OR "stromal sarcoma, endometrial" OR "stromal sarcoma, endometrial, malignant" OR "stromal sarcomas, endometrial" OR "Sarcoma, Endometrial Stromal"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 9 interventional · 2 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"sarcoma"
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: ESS
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (3585) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T09:36:17.999Z
